53biologics

Biotechnology Development for Industry in Pharmaceuticals, S. L. U. is a biotechnology firm focused on facilitating the commercial application of bioprocess technologies across various sectors, particularly in pharmaceuticals and nutraceuticals.

Founded in Valladolid, Spain, Biotechnology Development for Industry in Pharmaceuticals, S. L. U. specializes in bioprocess development.

The company has raised EUR 7 million in its most recent funding round on September 10, 2021, from Inveready Asset Management. Jorge Esteban is the founder, who has experience in initiating biotechnology ventures. There are no mentions of subsidiaries or significant business pivots. Biotechnology Development for Industry in Pharmaceuticals, S.

L. U. provides a range of biotechnology services that aid in transitioning laboratory projects to commercial applications. Their services include R&D and manufacturing support, focusing on bioprocess development, strain development, and contract production in fields such as cosmetics, nutraceuticals, and live biotherapeutics.

The company addresses client needs by producing high-value microbial-based products, including dietary enzymes, probiotics, and bioethanol, catering to a varied clientele from startups to established brands. In 2023, Biotechnology Development for Industry in Pharmaceuticals, S. L. U.

reported a revenue of EUR 4,771,343. 60 and an EBITDA of EUR 2,360,339. 80. Their revenue model is based on project-specific partnerships and B2B transactions, focusing on specialized services like strain development and bioprocess optimization for their clients.

Following the EUR 7 million raised in September 2021, Biotechnology Development for Industry in Pharmaceuticals, S. L. U. aims to support both organic and inorganic growth strategies.

They plan to design new products targeting advancements in bioprocess technologies and aim to expand into new geographic markets across Europe and beyond by 2023. In March 2026, 53Biologics raised an undisclosed amount of venture funding led by Ren Life Sciences, with participation from Inveready Asset Management.